Here are three things to know.
1. The organizations will use Optum’s claims and clinical records data to create and assess valued-based prescription payment models.
2. Optum and Merck will publicly share their assessments of the payment models “to help inform and facilitate the understanding and use of pragmatic approaches to [outcomes-based risk sharing agreements] in the healthcare system.
3. The partnership is the latest in a growing number of valued-based reimbursement collaborations for prescription drug payments.
- Bloomfield, Con.-based Cigna has entered seven outcomes-based deals since 2009, according to Bloomberg.
- Danish drugmaker Novo Nordisk recently signed its first pay-for-performance contract with Louisville, Ky.-based Humana for the diabetes treatment Victoza.
- Novartis, Amgen, Sanofi and Eli Lilly & Co., have also signed similar contracts with various insurers in the past year, according to the report.
More articles on payer issues:
7 questions about UnitedHealth’s false claims lawsuits, answered
How Aetna, Anthem, Humana and UnitedHealth fared in Q1
CMS seeks to remove small business plan enrollment from ACA marketplace: 3 things to know
